New first trimester circulating angiogenic biomarkers in predicting early-onset and late-onset fetal growth restriction: a case-control study

新的妊娠早期循环血管生成生物标志物在预测早发型和晚发型胎儿生长受限中的作用:一项病例对照研究

阅读:2

Abstract

BACKGROUND: First trimester prediction of fetal growth restriction (FGR) remain suboptimal. We aimed to search for new circulating angiogenic biomarkers for improvement. METHODS: This case-control study compared 73 singleton pregnancies with early or late-onset FGR based on Delphi consensus and 73 matched normal controls. Their maternal serum samples stored during 11-13 weeks were retrieved for measurement of 36 angiogenic biomarkers by MILLIPLEX(®) human angiogenesis magnetic bead panels. Those biomarkers that showed significant differences between the study groups were further analysed with receiver operating characteristic (ROC) curve. RESULTS: In the early-onset FGR group, log(10)MoM of soluble neuropilin-1 (sNRP-1: 0.08 ± 0.11 vs. 0.00 ± 0.09, P < 0.001) and log(10)MoM of soluble platelet and endothelial cell adhesion molecule 1 (sPECAM-1: 0.05 ± 0.06 vs. 0.00 ± 0.09, P < 0.05) were significantly higher than the control group, while log(10)MoM of platelet-derived growth factor AB/BB (PDGF-AB/BB: -0.08 ± 0.13 vs. 0.00 ± 0.16, P < 0.05) and PAPP-A (-0.15 ± 0.28 vs. 0.05 ± 0.23, P < 0.001) were lower. Their combination achieved the highest area under the ROC curve (AUC) of 0.83 (95% CI: 0.74-0.95) with a higher sensitivity than that of PAPP-A alone (61.5% vs. 30.8% at 10% false positive rate, P < 0.001). Concerning the late-onset FGR group, only log(10)MoMs of sFlt-1 (-0.12 vs. 0.00, P < 0.001) and PAPP-A (-0.07 vs. 0.05, P < 0.05) were lower than the control group, but their AUC was only 0.68 (95% CI:0.59-0.78). CONCLUSIONS: Three new first trimester biomarkers, sNRP-1, sPECAM-1 and PDGF-AB/BB are predictive of subsequent development of early-onset FGR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。